Cargando…

Eukaryotic translation initiation factors as promising targets in cancer therapy

The regulation of the translation of messenger RNA (mRNA) in eukaryotic cells is critical for gene expression, and occurs principally at the initiation phase which is mainly regulated by eukaryotic initiation factors (eIFs). eIFs are fundamental for the translation of mRNA and as such act as the pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Peiqi, Yu, Jiaojiao, Ward, Richard, Liu, Yin, Hao, Qiao, An, Su, Xu, Tianrui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640403/
https://www.ncbi.nlm.nih.gov/pubmed/33148274
http://dx.doi.org/10.1186/s12964-020-00607-9
_version_ 1783605740802408448
author Hao, Peiqi
Yu, Jiaojiao
Ward, Richard
Liu, Yin
Hao, Qiao
An, Su
Xu, Tianrui
author_facet Hao, Peiqi
Yu, Jiaojiao
Ward, Richard
Liu, Yin
Hao, Qiao
An, Su
Xu, Tianrui
author_sort Hao, Peiqi
collection PubMed
description The regulation of the translation of messenger RNA (mRNA) in eukaryotic cells is critical for gene expression, and occurs principally at the initiation phase which is mainly regulated by eukaryotic initiation factors (eIFs). eIFs are fundamental for the translation of mRNA and as such act as the primary targets of several signaling pathways to regulate gene expression. Mis-regulated mRNA expression is a common feature of tumorigenesis and the abnormal activity of eIF complexes triggered by upstream signaling pathways is detected in many tumors, leading to the selective translation of mRNA encoding proteins involved in tumorigenesis, metastasis, or resistance to anti-cancer drugs, and making eIFs a promising therapeutic target for various types of cancers. Here, we briefly outline our current understanding of the biology of eIFs, mainly focusing on the effects of several signaling pathways upon their functions and discuss their contributions to the initiation and progression of tumor growth. An overview of the progress in developing agents targeting the components of translation machinery for cancer treatment is also provided. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-020-00607-9.
format Online
Article
Text
id pubmed-7640403
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76404032020-11-04 Eukaryotic translation initiation factors as promising targets in cancer therapy Hao, Peiqi Yu, Jiaojiao Ward, Richard Liu, Yin Hao, Qiao An, Su Xu, Tianrui Cell Commun Signal Review The regulation of the translation of messenger RNA (mRNA) in eukaryotic cells is critical for gene expression, and occurs principally at the initiation phase which is mainly regulated by eukaryotic initiation factors (eIFs). eIFs are fundamental for the translation of mRNA and as such act as the primary targets of several signaling pathways to regulate gene expression. Mis-regulated mRNA expression is a common feature of tumorigenesis and the abnormal activity of eIF complexes triggered by upstream signaling pathways is detected in many tumors, leading to the selective translation of mRNA encoding proteins involved in tumorigenesis, metastasis, or resistance to anti-cancer drugs, and making eIFs a promising therapeutic target for various types of cancers. Here, we briefly outline our current understanding of the biology of eIFs, mainly focusing on the effects of several signaling pathways upon their functions and discuss their contributions to the initiation and progression of tumor growth. An overview of the progress in developing agents targeting the components of translation machinery for cancer treatment is also provided. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-020-00607-9. BioMed Central 2020-11-04 /pmc/articles/PMC7640403/ /pubmed/33148274 http://dx.doi.org/10.1186/s12964-020-00607-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Hao, Peiqi
Yu, Jiaojiao
Ward, Richard
Liu, Yin
Hao, Qiao
An, Su
Xu, Tianrui
Eukaryotic translation initiation factors as promising targets in cancer therapy
title Eukaryotic translation initiation factors as promising targets in cancer therapy
title_full Eukaryotic translation initiation factors as promising targets in cancer therapy
title_fullStr Eukaryotic translation initiation factors as promising targets in cancer therapy
title_full_unstemmed Eukaryotic translation initiation factors as promising targets in cancer therapy
title_short Eukaryotic translation initiation factors as promising targets in cancer therapy
title_sort eukaryotic translation initiation factors as promising targets in cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640403/
https://www.ncbi.nlm.nih.gov/pubmed/33148274
http://dx.doi.org/10.1186/s12964-020-00607-9
work_keys_str_mv AT haopeiqi eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy
AT yujiaojiao eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy
AT wardrichard eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy
AT liuyin eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy
AT haoqiao eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy
AT ansu eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy
AT xutianrui eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy